DealForma

Early-stage biopharma funding in 2026 YTD remained concentrated in biologics and cancer, although overall investment is running below 2025 levels in several major categories. Find additional biopharma deal data and charts on DealForma.

Biopharma R&D partnerships kept their pace in Q3 2026, but the deals were worth far less in total. The number of deals rose slightly, and the typical upfront payment grew. However, fewer and smaller deals drove the drop in total value. Read our research na2.hubs.ly/H08NSnt0

Biopharma venture rounds grew larger across most development stages in 2026 YTD. Find additional biopharma deal data and charts on DealForma.

Later-stage biopharma venture financing continued to attract more capital than first-round funding in 2026 YTD. Find additional biopharma deal data and charts on DealForma.

UK and Swiss biopharma led European venture fundraising through Q3 2026. Find additional biopharma deal data and charts on DealForma.

Biopharma venture activity remained concentrated in the largest U.S. life sciences hubs through Q3 2026. Find additional biopharma deal data and charts on DealForma.

AI/ML has become one of the largest destinations for biopharma venture capital in 2025–2026 YTD. Find additional biopharma deal data and charts on DealForma.

Biopharma venture activity slowed across financing stages in Q3 2026. Find additional biopharma deal data and charts on DealForma.

Biopharma venture investment pulled back in Q3 2026 after a stronger first half. Find additional biopharma deal data and charts on DealForma.

Discovery-stage licensing in 2025–2026 YTD has been concentrated around antibodies, small molecules, and AI/ML platforms. Find additional biopharma deal data and charts on DealForma.

AI-based target and drug discovery licensing continued to climb in 2026. Find additional biopharma deal data and charts on DealForma.

Large-cap biopharma continued to concentrate in-licensing activity at the earliest stages in 2026. Find additional biopharma deal data and charts on DealForma.

Discovery-stage licensing in 2025–2026 YTD has been dominated by antibodies, small molecules, and AI/ML platforms. Find additional biopharma deal data and charts on DealForma.

AI-based target and drug discovery licensing accelerated sharply in 2026. Find additional biopharma deal data and charts on DealForma.

Oncology R&D partnership activity remains substantial in 2026, with deal values holding up despite fewer transactions. Find additional biopharma deal data and charts on DealForma.

Biopharma dealmaking lost momentum in Q3 2026, with M&A, licensing, and venture investment declining after a strong first half of the year. The article features DealForma's quarterly analysis Read it here na2.hubs.ly/H08z-2Z0

Explore the latest biopharma and medtech dealmaking trends in J.P. Morgan’s reports, featuring data provided by DealForma, and download the reports for insights into licensing, M&A, and financing activity. View them here na2.hubs.ly/H08yF6k0

ADC dealmaking remains active in 2026, with median upfront payments rising sharply even as overall deal volume remains below 2025. Find additional biopharma deal data and charts on DealForma.

Large-cap biopharma continued to concentrate in-licensing spending in oncology and biologic modalities through 2026 YTD. Find additional biopharma deal data and charts on DealForma.

J.P. Morgan’s latest Biopharma and Medtech Licensing and Venture Reports, with data provided by DealForma, offer a comprehensive look at licensing, M&A, venture funding, and IPO activity in the first half of 2026. Download them here na2.hubs.ly/H08yB4d0